Abstract
Background: Long non-coding ribonucleic acid (lncRNA) are known as similar transcripts of messenger RNA (mRNA) whose size discrepancy is between 100 and 200 nucleotides. Recent studies in this area have revealed that lncRNAs are involved in cancer tumorigenesis and progression. Such molecules are transcribed from genome regions that lack open reading frame (ORF) and fail to encode any protein. LncRNAs are characterized by tumorigenic behaviors, which can be considered as new biomarkers. Among all types of thyroid cancer (TC), papillary thyroid carcinoma (PTC) is the most common one.
Methods: This review was prepared via searching of the databases of Science Direct, Directory of Open Access Journals (DOAJ), Google Scholar, Pub-Med (NLM), Scopus, Web of Science, and hand searching using relative keywords. The selected papers were fully reviewed and the required information for the review was extracted and summarized.
Results: Previous studies indicated that BRAF-activated non-protein coding RNA (BANCR) expression had been increased in thyroid tumors compared with adjacent normal tissues. Additionally, BANCR had mediated epithelial-mesenchymal transition (EMT) through regulating the expression of epithelial (E)-cadherin, vimentin, and neuronal (N)-cadherin. Moreover, H19 was an example of a lncRNA that could function either as a tumor promoter or suppressor. An important part of this study was dedicated to reviewing signaling pathways involved in TC including extracellular-signal-regulated kinase (ERK) pathway and mitogen-activated protein kinase (ERK/MAPK), transforming growth factor-β/ (TGF-ß)/Smads, the Janus kinase/signal transducers and activators of transcription (JAK/STAT), P53, as well as other pathways.
Conclusion: Briefly, this study provided an overview of the current understanding of the function of lncRNA and micro RNAs (miRNAs) along with their interactions in TC.
Keywords: Long Non-Coding RNA, Thyroid Cancer, Signaling Pathway, papillary thyroid carcinoma, H19, extracellularsignal- regulated kinase.
Current Signal Transduction Therapy
Title:Trace of Long Non-Coding RNAs in Signaling Pathways in Thyroid Cancer
Volume: 16 Issue: 2
Author(s): Mohsen Safaei, Ameneh Mehri-Ghahfarrokhi and Ali Shojaeian*
Affiliation:
- Department of Molecular Medicine, School of Advanced Technologies, Shahrekord University of Medical Sciences, Shahrekord,Iran
Keywords: Long Non-Coding RNA, Thyroid Cancer, Signaling Pathway, papillary thyroid carcinoma, H19, extracellularsignal- regulated kinase.
Abstract:
Background: Long non-coding ribonucleic acid (lncRNA) are known as similar transcripts of messenger RNA (mRNA) whose size discrepancy is between 100 and 200 nucleotides. Recent studies in this area have revealed that lncRNAs are involved in cancer tumorigenesis and progression. Such molecules are transcribed from genome regions that lack open reading frame (ORF) and fail to encode any protein. LncRNAs are characterized by tumorigenic behaviors, which can be considered as new biomarkers. Among all types of thyroid cancer (TC), papillary thyroid carcinoma (PTC) is the most common one.
Methods: This review was prepared via searching of the databases of Science Direct, Directory of Open Access Journals (DOAJ), Google Scholar, Pub-Med (NLM), Scopus, Web of Science, and hand searching using relative keywords. The selected papers were fully reviewed and the required information for the review was extracted and summarized.
Results: Previous studies indicated that BRAF-activated non-protein coding RNA (BANCR) expression had been increased in thyroid tumors compared with adjacent normal tissues. Additionally, BANCR had mediated epithelial-mesenchymal transition (EMT) through regulating the expression of epithelial (E)-cadherin, vimentin, and neuronal (N)-cadherin. Moreover, H19 was an example of a lncRNA that could function either as a tumor promoter or suppressor. An important part of this study was dedicated to reviewing signaling pathways involved in TC including extracellular-signal-regulated kinase (ERK) pathway and mitogen-activated protein kinase (ERK/MAPK), transforming growth factor-β/ (TGF-ß)/Smads, the Janus kinase/signal transducers and activators of transcription (JAK/STAT), P53, as well as other pathways.
Conclusion: Briefly, this study provided an overview of the current understanding of the function of lncRNA and micro RNAs (miRNAs) along with their interactions in TC.
Export Options
About this article
Cite this article as:
Safaei Mohsen , Mehri-Ghahfarrokhi Ameneh and Shojaeian Ali *, Trace of Long Non-Coding RNAs in Signaling Pathways in Thyroid Cancer, Current Signal Transduction Therapy 2021; 16 (2) . https://dx.doi.org/10.2174/1574362415666200211104406
DOI https://dx.doi.org/10.2174/1574362415666200211104406 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Ghrelin and Energy Balance: Focus on Current Controversies
Current Drug Targets Rac-1 as a New Therapeutic Target in Cerebro- and Cardio-Vascular Diseases
Current Drug Targets Estrogen Receptor Signaling: Impact on Cell Functions
Current Signal Transduction Therapy Novel Immunotherapies for Hematological Malignancies
Current Molecular Pharmacology Antibodies Against Muscarinic Receptors in Breast Cancer: Agonizing Tumor Growth
Current Immunology Reviews (Discontinued) Steroid Biosynthesis Inhibitors in the Therapy of Hypercortisolism: Theory and Practice
Current Medicinal Chemistry <i>Prunella vulgaris</i> L: Critical Pharmacological, Expository Traditional Uses and Extensive Phytochemistry: A Review
Current Drug Discovery Technologies The Human Indoleamine 2,3-Dioxygenase Gene and Related Human Genes
Current Drug Metabolism A Historical Overview of the Heterologous Expression of Mammalian UDP-Glucuronosyltransferase Isoforms Over the Past Twenty Years
Current Drug Metabolism The CXCL12/CXCR4 Axis as a Therapeutic Target in Cancer and HIV-1 Infection
Current Medicinal Chemistry Limiting Functional Deficiency Following Stroke: Exploiting Different Stem Cell Reservoirs
Current Neuropharmacology Basic and Clinical Research Against Advanced Glycation End Products (AGEs): New Compounds to Tackle Cardiovascular Disease and Diabetic Complications
Recent Advances in Cardiovascular Drug Discovery (Discontinued) D-Galactose as a Vector for Prodrug Design
Current Topics in Medicinal Chemistry Editorial (Thematic Issue: Treating Major Age-Related Diseases in Older and Oldest Old Patients)
Current Pharmaceutical Design Novel Drug-Induced Pulmonary Complications in Cancer Patients You Can Save Life!
Current Respiratory Medicine Reviews Molecular Biomarkers for Lung Adenocarcinoma: A Short Review
Current Cancer Therapy Reviews Subclinical Hypothyroidism and Homeostatic Disturbances: Case Report and Literature Review
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Editorial [Hot topic:Targeted Molecular Radiotherapy (Guest Editor: Veerle Kersemans)]
Current Drug Discovery Technologies Dynamic Localization of Hepatocellular Transporters: Role in Biliary Excretion and Impairment in Cholestasis
Current Medicinal Chemistry Endoglin-Targeted Cancer Therapy
Current Drug Delivery